Advertisement

Aegerion Pharmaceuticals Inc. (Nasdaq:AEGR), received positive data from a Phase 3 trial of its potential treatment for a rare genetic type of extremely high cholesterol, sending the company’s stock up more than 4 percent.

The Cambridge-based biotechnology company said that 56-week data for the drug candidate, called lomitapide, showed the drug target was just as effective as earlier 26-week data had shown. Also, 13 of the 23 patients in the study were able to reduce the amount of other lipid-lowering drugs they were taking, the company said.

SOURCE

Advertisement
Advertisement